연구동향 분석

Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma who Received Systemic Treatment

박창희 김미소 곽윤진 문경철 김세현 김범석 김유정 김태민 김동완 년

논문상세정보
인용/피인용

' Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma who Received Systemic Treatment' 의 참고문헌

  • WHO classification of tumours of soft tissue and bone
    Fletcher CD [2013]
  • Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases
    Frentzas S [2016]
  • Treatment and outcome of 82patients with angiosarcoma
    Abraham JA [2007]
  • The pharmacological bases of the antiangiogenic activity of paclitaxel
    Bocci G [2013]
  • The impact of de novo liver metastasis on clinical outcome in patients with advanced non-small-cell lung cancer
    Chang YP [2017]
  • Targeting angiosarcomas of the soft tissues : a challenging effort in a heterogeneous and rare disease
    Weidema ME [2019]
  • Recurrent PTPRB and PLCG1 mutations in angiosarcoma
    Behjati S [2014]
  • Phase II trial of weekly paclitaxel for unresectable angiosarcoma : the ANGIOTAX Study
    Penel N [2008]
  • Pazopanib in advanced vascular sarcomas : an EORTC Soft Tissue and Bone Sarcoma Group(STBSG)retrospective analysis
    Kollar A [2017]
  • Pazopanib for metastatic soft-tissue sarcoma(PALETTE) : a randomised, double-blind, placebo-controlled phase 3 trial
  • Pazopanib : Clinical development of a potent anti-angiogenic drug
    Schutz FA [2011]
  • Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma : a randomized phase II trial
  • New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
  • Metastatic angiosarcomas : doxorubicinbased regimens, weekly paclitaxel and metastasectomy significantly improve the outcome
    Penel N [2012]
  • MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas
    Zietz C [1998]
  • Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC
    Tumeh PC [2017]
  • Hepatic angiosarcoma manifested as recurrent hemoperitoneum
    Lee SW [2008]
  • First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes : pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials
    Young RJ [2014]
  • Endothelial cell malignancies : new insights from the laboratory and clinic
    Wagner MJ [2017]
  • Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas
    Itakura E [2008]
  • Common terminology criteria for adverse events, v5.0
  • Clinicopathological features and prognostic factors in angiosarcoma : A retrospective analysis of 200 patients from a single Chinese medical institute
    Wang L [2017]
  • Autocrine and paracrine roles of VEGF/VEGFR-2 and VEGF-C/VEGFR-3 signaling in angiosarcomas of the scalp and face
    Tokuyama W [2010]
  • Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site : a retrospective study of 161 cases
    Fayette J [2007]
  • Angiosarcoma : state of the art and perspectives
    Penel N [2011]
  • Angiosarcoma : clinical and molecular insights
    Lahat G [2010]
  • Angiosarcoma
    Young RJ [2010]
  • An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas
    Agulnik M [2013]
  • Acute liver failure due to primary angiosarcoma : a case report and review of literature
    Bhati CS [2008]
  • A Korean single-center, real-world, retrospective study of firstline weekly paclitaxel in patients with metastatic angiosarcoma
    Byeon S [2016]